Armata Pharmaceuticals, Inc. (FRA:TG1N)

Market Cap	269.78M +280.8%
Revenue (ttm)	4.31M -7.6%
Net Income	-39.97M
EPS	-1.89
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	123
Open	7.05
Previous Close	6.75
Day's Range	7.05 - 7.05
52-Week Range	0.70 - 7.05
Beta	n/a
RSI	65.29
Earnings Date	Mar 16, 2026

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing syn...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Deborah Birx
• Employees: 60
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TG1N

Financial Performance

In 2024, Armata Pharmaceuticals's revenue was $5.17 million, an increase of 14.24% compared to the previous year's $4.53 million. Losses were -$18.92 million, -72.60% less than in 2023.

Financial numbers in USD